Evidence map›Paper›PMID 39695972›Full record

ArticleBMC infectious diseases2024

Competing risks multi-state model for time-to-event data analysis of HIV/AIDS: a retrospective cohort national datasets, Ethiopia.

Tsegaye H Kumssa, Andargachew Mulu, Adane Mihret, Zeytu G Asfaw

Abstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tsegaye H KumssaDepartment of Statistics, Hawassa University, Hawassa, Ethiopia. tsegaye.hailu@ahri.gov.et.
Andargachew MuluArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Adane MihretArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Zeytu G AsfawDepartment of Epidemiology and Biostatistics, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTuberculosis (TB) remains the most common opportunistic infection and leading cause of death among individuals living with HIV/AIDS in Ethiopia. Its significant impact on morbidity and mortality underscores the crucial link between these two diseases. While the advent of antiretroviral therapy (ART) has led to a dramatic decline in mortality rates among HIV/AIDS patients, TB continues to pose a substantial threat. This study aims to estimate the probability of death due to TB among HIV/AIDS patients on ART, considering the presence of various competing risks, including diarrhea, other infections, and unknown/unspecified causes. Also we have assessed the effects of prognostic factors on HIV/AIDS cause specific deaths, compared with the death from other competing risks, and exploring leading cause of death among HIV/AIDS patients on Antiretroviral Therapy.

methodsData from a retrospective research examining the effectiveness of antiretroviral therapy (ART) in Ethiopia were used in this investigation. The data came from medical records of patients who were part of the national ART program. A total of 39,590 records were gathered between October 2019 and March 2020 from all regions of Ethiopia as well as the administration cities of Addis Ababa and Dire Dawa. The study facilities were grouped using a multi-stage sample technique and simple random selection was used to select health facility and a person record from medical records. In the presence of the competing causes of death, Cause specific hazard, subdistribution hazard model and flexible parametric proportional hazard model have been used to assess the effect of covariates on the risk of death, with the cmprisk package in R4.3.2 software.

resultsOut of the total 1212 deaths, 542(44.7%) died competing with other opportunistic infection (TE-Esophageal Candidiasis, TO-oral, CT-CNS Toxoplasmosis, CM-Crypotococcal Meningitis…), 421 (34.7%) died due to tuberculosis and the remaining death were unknown/Not specified infection 222(18.3%) and diarrhea 27(2.2%). Rates of mortality caused by tuberculosis, competing with other opportunistic infection, diarrhea and unknown/Not specified were 3.5, 4.5, 0.2 and 1.8 per 1000 person-months, respectively. Having a higher CD4 count at diagnosis, responding to combination antiretroviral treatment (cART) six months after start, and having prophylactic treatment for pneumocystis pneumonia (PCP) decreased the risk of tuberculosis, other opportunistic infections, and unidentified and diarrheal causes of death. However, older age, late HIV.AIDS diagnosis, and the last HIV/AIDS WHO clinical stages increased the hazard of tuberculosis and other opportunistic disease mortality. Additionally, male gender, older age and last HIV clinical stages increased the mortality HIV/AIDS patients.

conclusionThe findings of this study demonstrated that TB, an opportunistic infection, was the primary cause of death in HIV/AIDS patients, despite the presence of several competing risks, such as diarrhea, other infections, and an undetermined or unclear cause. It's important to use effective techniques to quickly detect those who have HIV or AIDS and provide them with care and treatment to increase their chances of surviving.

Indexed as

HIV InfectionsAcquired Immunodeficiency SyndromeAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Retroviral AgentsCause of DeathChildData AnalysisEthiopiaFemaleHumansMaleMiddle AgedRetrospective StudiesAnti-HIV AgentsAnti-Retroviral AgentsAIDS·Cause-specific hazardCompeting riskCumulative Incidence Function·Sub-distribution hazard

Identifiers

PMID39695972
PMCPMC11654082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.